{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"8"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"title":"Possible worsened vision"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}],"title":"Definite worsened vision"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"11"}],"units":"Participants"}],"title":"Left Eye"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"10"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}],"title":"Possible worsened vision"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"title":"Definite worsened vision"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"11"}],"units":"Participants"}],"title":"Right Eye"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"11"}],"units":"Participants"}],"description":"Change in BCVA is defined as change in logarithm of the minimum angle of resolution (logMAR) units compared with baseline or the first visit after the cataract surgery. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any change from baseline categories is presented for right and left eyes. No change/improved vision is defined as a change from baseline \\<0.1; a possible worsened vision is defined as a change from baseline \\>=0.1 to \\<=0.3; a definite worsened vision is defined as a change from baseline \\>0.3 logMAR score. Improvement in BCVA is represented by a reduction in logMAR score from baseline, while worsening in BCVA is represented by an increase in logMAR score from baseline.","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose on Day 1 of every 3 weeks (Q3W) as a 30-60 minute intravenous (IV) infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG000","title":"Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q3W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG001","title":"Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every 6 weeks (Q6W) as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG002","title":"Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG003","title":"Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death. For this arm, dose modification decisions were determined by the results of the Ocular Surface Disease Index (OSDI) questionnaire or VA assessments using Snellen chart. The OSDI scale assesses the severity of eye symptoms and their impact and Snellen chart is for the assessment of visual acuity.","id":"OG004","title":"Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to 152 weeks","title":"Number of Participants With Change in Best Corrected Visual Acuity Test (BCVA) Scores","type":"SECONDARY","unitOfMeasure":"Participants"}